These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 35068797)

  • 21. Cost Effectiveness of Different Strategies for Detecting Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Based on United States Health Care System.
    Vilar-Gomez E; Lou Z; Kong N; Vuppalanchi R; Imperiale TF; Chalasani N
    Clin Gastroenterol Hepatol; 2020 Sep; 18(10):2305-2314.e12. PubMed ID: 32289535
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MR elastography-based liver fibrosis correlates with liver events in nonalcoholic fatty liver patients: A multicenter study.
    Han MAT; Vipani A; Noureddin N; Ramirez K; Gornbein J; Saouaf R; Baniesh N; Cummings-John O; Okubote T; Setiawan VW; Rotman Y; Loomba R; Alkhouri N; Noureddin M
    Liver Int; 2020 Sep; 40(9):2242-2251. PubMed ID: 32652744
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How histopathologic changes in pediatric nonalcoholic fatty liver disease influence in vivo liver stiffness.
    Hudert CA; Tzschätzsch H; Rudolph B; Loddenkemper C; Holzhütter HG; Kalveram L; Wiegand S; Braun J; Sack I; Guo J
    Acta Biomater; 2021 Mar; 123():178-186. PubMed ID: 33472102
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of MRE versus VCTE in staging fibrosis for nonalcoholic fatty liver disease (NAFLD) patients with advanced fibrosis.
    Sangha K; Chang ST; Cheung R; Deshpande VS
    Hepatology; 2023 May; 77(5):1702-1711. PubMed ID: 37018145
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of Imaging Modalities Against Liver Biopsy in Nonalcoholic Fatty Liver Disease: The Amsterdam NAFLD-NASH Cohort.
    Troelstra MA; Witjes JJ; van Dijk AM; Mak AL; Gurney-Champion O; Runge JH; Zwirs D; Stols-Gonçalves D; Zwinderman AH; Ten Wolde M; Monajemi H; Ramsoekh S; Sinkus R; van Delden OM; Beuers UH; Verheij J; Nieuwdorp M; Nederveen AJ; Holleboom AG
    J Magn Reson Imaging; 2021 Dec; 54(6):1937-1949. PubMed ID: 33991378
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease.
    Castera L; Friedrich-Rust M; Loomba R
    Gastroenterology; 2019 Apr; 156(5):1264-1281.e4. PubMed ID: 30660725
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study.
    Loomba R; Wolfson T; Ang B; Hooker J; Behling C; Peterson M; Valasek M; Lin G; Brenner D; Gamst A; Ehman R; Sirlin C
    Hepatology; 2014 Dec; 60(6):1920-8. PubMed ID: 25103310
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel 3D Magnetic Resonance Elastography for the Noninvasive Diagnosis of Advanced Fibrosis in NAFLD: A Prospective Study.
    Loomba R; Cui J; Wolfson T; Haufe W; Hooker J; Szeverenyi N; Ang B; Bhatt A; Wang K; Aryafar H; Behling C; Valasek MA; Lin GY; Gamst A; Brenner DA; Yin M; Glaser KJ; Ehman RL; Sirlin CB
    Am J Gastroenterol; 2016 Jul; 111(7):986-94. PubMed ID: 27002798
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of Ultrasound Methods for the Assessment of NAFLD.
    Petzold G
    J Clin Med; 2022 Aug; 11(15):. PubMed ID: 35956196
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatocellular Carcinoma and Non-Alcoholic Fatty Liver Disease: A Step Forward for Better Evaluation Using Ultrasound Elastography.
    Lupsor-Platon M; Serban T; Silion AI; Tirpe A; Florea M
    Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 32998257
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: The Prognostic Role of Liver Stiffness Measurement.
    Cerrito L; Mignini I; Ainora ME; Mosoni C; Gasbarrini A; Zocco MA
    Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765595
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Utility of an Increase in Magnetic Resonance Elastography in Predicting Fibrosis Progression in Nonalcoholic Fatty Liver Disease.
    Ajmera VH; Liu A; Singh S; Yachoa G; Ramey M; Bhargava M; Zamani A; Lopez S; Mangla N; Bettencourt R; Rizo E; Valasek M; Behling C; Richards L; Sirlin C; Loomba R
    Hepatology; 2020 Mar; 71(3):849-860. PubMed ID: 31556124
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liver Stiffness by Magnetic Resonance Elastography Predicts Future Cirrhosis, Decompensation, and Death in NAFLD.
    Gidener T; Ahmed OT; Larson JJ; Mara KC; Therneau TM; Venkatesh SK; Ehman RL; Yin M; Allen AM
    Clin Gastroenterol Hepatol; 2021 Sep; 19(9):1915-1924.e6. PubMed ID: 33010409
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Application of the combined FibroMeter vibration-controlled transient elastography algorithm in Chinese patients with non-alcoholic fatty liver disease.
    Loong TC; Wei JL; Leung JC; Wong GL; Shu SS; Chim AM; Chan AW; Choi PC; Tse YK; Chan HL; Wong VW
    J Gastroenterol Hepatol; 2017 Jul; 32(7):1363-1369. PubMed ID: 27936280
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MR elastography is effective for the non-invasive evaluation of fibrosis and necroinflammatory activity in patients with nonalcoholic fatty liver disease.
    Costa-Silva L; Ferolla SM; Lima AS; Vidigal PVT; Ferrari TCA
    Eur J Radiol; 2018 Jan; 98():82-89. PubMed ID: 29279175
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Magnetic resonance-based biomarkers in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Caussy C; Johansson L
    Endocrinol Diabetes Metab; 2020 Oct; 3(4):e00134. PubMed ID: 33102797
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Noninvasive Markers of Fibrosis and Inflammation in Nonalcoholic Fatty Liver Disease.
    Jayakumar S; Harrison SA; Loomba R
    Curr Hepatol Rep; 2016 Jun; 15(2):86-95. PubMed ID: 27795938
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Magnetic resonance imaging for the assessment of pathological hepatic findings in nonalcoholic fatty liver disease.
    Imajo K; Honda Y; Yoneda M; Saito S; Nakajima A
    J Med Ultrason (2001); 2020 Oct; 47(4):535-548. PubMed ID: 33108553
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis.
    Xiao G; Zhu S; Xiao X; Yan L; Yang J; Wu G
    Hepatology; 2017 Nov; 66(5):1486-1501. PubMed ID: 28586172
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Two-dimensional Shear Wave Elastography with Propagation Maps for the Assessment of Liver Fibrosis and Clinically Significant Portal Hypertension in Patients with Chronic Liver Disease: A Prospective Study.
    Jeon SK; Lee JM; Joo I; Yoon JH; Lee DH; Han JK
    Acad Radiol; 2020 Jun; 27(6):798-806. PubMed ID: 31494001
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.